
Willow bark for arthritis pain: newer pooled results do not erase negative trials
Willow-bark evidence includes a favorable recent meta-analysis and randomized trials that found no meaningful benefit over placebo.
Willow bark has inconsistent arthritis evidence, and salicylate-related safety concerns make it inappropriate to treat as gentle aspirin.
Aspirin history does not make willow bark predictable
Willow bark contains salicin-related compounds and has a long history in pain remedies. That connection to aspirin can make the product seem both proven and familiar. In practice, a botanical extract contains multiple constituents, and its delivered salicin amount, absorption and manufacturing consistency can differ from a regulated medicine. Historical lineage is not a clinical comparison.
NCCIH says only a small amount of evidence suggests willow bark might help chronic low-back pain or osteoarthritis. The narrow wording matters. It does not establish that any tea, powder or extract relieves arthritis, and it does not identify a benefit large enough to outweigh risk in a specific user.

Two randomized trials were not persuasive
A six-week randomized double-blind osteoarthritis trial compared standardized willow-bark extract, diclofenac and placebo in 127 people with hip or knee disease. Pain decreased slightly in the willow group, but the difference from placebo was not statistically significant. Diclofenac separated clearly from placebo under the same design.
A companion rheumatoid-arthritis trial enrolled only 26 people and likewise found no significant advantage for willow bark. Rheumatoid arthritis and osteoarthritis are different conditions, so neither result can be transferred casually. Together the trials show why a mechanism and traditional use should not be treated as substitutes for an adequate placebo-controlled effect.
A 2023 meta-analysis was more favorable but uncertain
A meta-analysis published in 2023 combined six randomized comparisons involving 329 people with arthritis and reported improvements in pain and physical status. The authors nevertheless rated the certainty inadequate because of potential bias and called for more randomized trials. A pooled estimate can be statistically positive while the underlying evidence remains fragile.
Review results depend on which trials, diagnoses, outcome scales and time points are combined. Small studies receive less weight but can still influence the total. The negative 2004 trials do not disappear when pooled with favorable research; they become part of an inconsistent record that should be reflected in consumer-facing claims.
Salicylate-like risks deserve attention
Willow bark can cause gastrointestinal symptoms and may be unsuitable for people with aspirin sensitivity, bleeding risk, kidney disease or certain other conditions. Anticoagulants, antiplatelet drugs, nonsteroidal anti-inflammatory medicines and other products affecting bleeding can change the safety calculation. Children and adolescents with viral illness should not be given salicylate-containing remedies.
A product marketed as natural pain relief may not display risk with the same prominence as benefit. Consumers should compare the standardized salicin amount and all co-ingredients, then bring the actual label to a pharmacist or clinician. Switching from an established medicine to willow bark without review is not a safety strategy.

How to interpret the mixed record
The fair conclusion is uncertainty, not a choice between “ancient cure” and “useless herb.” Some pooled evidence is favorable, while well-described trials failed to show meaningful superiority over placebo. Larger independent studies using characterized extracts, prespecified outcomes and longer safety follow-up would make the estimate more dependable.
Until then, willow bark should not be credited with cartilage repair or disease modification. If considered at all, the goal should be a specific symptom outcome during a defined period, with attention to bleeding and medicine interactions. A lack of noticeable benefit should lead to reassessment rather than dose escalation based on the assumption that botanical products are inherently mild.
Why newer does not always mean more certain
A later review can search more databases, include additional trials and use improved statistical methods, but its conclusion is still limited by the studies it finds. If most participants came from small or biased trials, a recent publication date does not transform the source material into high-certainty evidence. Readers should inspect risk-of-bias judgments and the size of the largest well-controlled comparison.
The salicin standardization used in research is another practical boundary. Products may state willow-bark weight without clarifying the amount of relevant constituents, while teas deliver especially variable exposure. A consumer cannot reproduce a trial merely by choosing a larger serving. Product uncertainty and a mixed clinical record should make claims narrower, not encourage experimentation with increasingly concentrated amounts.
Sources & further reading
This article provides educational information. Ask a qualified clinician or pharmacist about your symptoms, medical conditions, medicines and supplement interactions.